A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis
Phase 3
Completed
NCT05489224
| Condition | Rheumatoid Arthritis |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Celltrion |
|---|
| Status | Completed |
|---|
| Enrollment | 471 participants |
|---|
| Interventions | CT-P47, EU-approved RoActemra |
|---|
| Start date | Sep 14, 2022 |
|---|
| Completion date | Jun 29, 2023 |
|---|
| Results posted | Oct 8, 2024 |
|---|
Summary
This is a phase 3 study to compare efficacy and safety of CT-P47 and RoActemra in patients with moderate to severe active rheumatoid arthritis.
Mean Change From Baseline in Disease Activity Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) at Week 24
Week 24 · units on a scale
| CT-P47 | -3.77 ± 0.120 units on a scale |
|---|
| RoActemra | -3.67 ± 0.118 units on a scale |
|---|
| Treatment difference and 90% CI | -0.10 (95% CI -0.30–0.10) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.